Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme

Oncogene

Volumn 32, Issue 7, 2013, Pages 872-882

  Wang, Y ^a   Moncayo, G ^a   Morin, P ^a,d   Xue, G ^a   Grzmil, M ^a   Lino, M M ^b   Clement Schatlo V ^c   Frank, S ^b   Merlo, A ^b,e   Hemmings, B A ^a  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITÉ DE MONCTON   (Canada)

^e NONE   (Switzerland)

Author keywords

actomyosin contractility; apoptosis; glioblastoma multiforme (GBM); invasiveness; MerTK

Indexed keywords

MUTANT PROTEIN; MYOSIN ADENOSINE TRIPHOSPHATASE; MYOSIN LIGHT CHAIN 2; NESTIN; PROTEIN TYROSINE KINASE; RECEPTOR TYROSINE KINASE MER; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; ASTROCYTE; AUTOPHOSPHORYLATION; CANCER INVASION; CELL INVASION; CELL MOTILITY; CELL STRUCTURE; CELL SURVIVAL; CONTROLLED STUDY; DEGLYCOSYLATION; DNA DAMAGE; ENZYME ACTIVITY; GENE SILENCING; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MESENCHYME CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MUSCLE CONTRACTILITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STEM CELL; TUMOR MICROENVIRONMENT;

EID: 84874112354     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.104     Document Type: Article

References (49)

1. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007; 21: 2683-2710.
2. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010; 60: 166-193.
3. Zhai GG, Malhotra R, Delaney M, Latham D, Nestler U, Zhang M et al. Radiation enhances the invasive potential of primary glioblastoma cells via activation of the Rho signaling pathway. J Neurooncol 2006; 76: 227-237.
4. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-760.
5. Bellail AC, Hunter SB, Brat DJ, Tan C, Van Meir EG. Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol 2004; 36: 1046-1069.
6. Beadle C, Assanah MC, Monzo P, Vallee R, Rosenfeld SS, Canoll P. The role of myosin II in glioma invasion of the brain. Mol Biol Cell 2008; 19: 3357-3368.
7. Graham DK, Dawson TL, Mullaney DL, Snodgrass HR, Earp HS. Cloning and mRNA expression analysis of a novel human protooncogene, c-mer. Cell Growth Differ 1994; 5: 647-657.
8. Linger RM, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res 2008; 100: 35-83.
9. Nagata K, Ohashi K, Nakano T, Arita H, Zong C, Hanafusa H et al. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem 1996; 271: 30022-30027.
10. Ling L, Templeton D, Kung HJ. Identification of the major autophosphorylation sites of Nyk/Mer, an NCAM-related receptor tyrosine kinase. J Biol Chem 1996; 271: 18355-18362.
11. Duncan JL, Yang H, Vollrath D, Yasumura D, Matthes MT, Trautmann N et al. Inherited retinal dystrophy in Mer knockout mice. Adv Exp Med Biol 2003; 533: 165-172.
12. Cohen PL, Caricchio R, Abraham V, Camenisch TD, Jennette JC, Roubey RA et al. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med 2002; 196: 135-140.
13. Hafizi S, Dahlback B. Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine Growth Factor Rev 2006; 17: 295-304.
14. Ling L, Kung HJ. Mitogenic signals and transforming potential of Nyk, a newly identified neural cell adhesion molecule-related receptor tyrosine kinase. Mol Cell Biol 1995; 15: 6582-6592.
15. Ek S, Hogerkorp CM, Dictor M, Ehinger M, Borrebaeck CA. Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. Cancer Res 2002; 62: 4398-4405.
16. Wu YM, Robinson DR, Kung HJ. Signal pathways in up-regulation of chemokines by tyrosine kinase MER/NYK in prostate cancer cells. Cancer Res 2004; 64: 7311-7320.
17. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451: 147-152.
18. Gyorffy B, Lage H. A Web-based data warehouse on gene expression in human malignant melanoma. J Invest Dermatol 2007; 127: 394-399.
19. Graham DK, Salzberg DB, Kurtzberg J, Sather S, Matsushima GK, Keating AK et al. Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia. Clin Cancer Res 2006; 12: 2662-2669.
20. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.
21. Grzmil M, Morin Jr P, Lino MM, Merlo A, Frank S, Wang Y et al. MAP kinaseinteracting kinase 1 regulates SMAD2-dependent TGF-beta signaling pathway in human glioblastoma. Cancer Res 2011; 71: 2392-2402.
22. Sather S, Kenyon KD, Lefkowitz JB, Liang X, Varnum BC, Henson PM et al. A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood 2007; 109: 1026-1033.
23. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006; 9: 391-403.
24. Gunther HS, Schmidt NO, Phillips HS, Kemming D, Kharbanda S, Soriano R et al. Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 2008; 27: 2897-2909.
25. Ropolo M, Daga A, Griffero F, Foresta M, Casartelli G, Zunino A et al. Comparative analysis of DNA repair in stem and nonstem glioma cell cultures. Mol Cancer Res 2009; 7: 383-392.
26. Pankova K, Rosel D, Novotny M, Brabek J. The molecular mechanisms of transition between mesenchymal and amoeboid invasiveness in tumor cells. Cell Mol Life Sci 2010; 67: 63-71.
27. Zhang M, Rao PV. Blebbistatin, a novel inhibitor of myosin II ATPase activity, increases aqueous humor outflow facility in perfused enucleated porcine eyes. Invest Ophthalmol Vis Sci 2005; 46: 4130-4138.
28. Keating AK, Kim GK, Jones AE, Donson AM, Ware K, Mulcahy JM et al. Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Mol Cancer Ther 2010; 9: 1298-1307.
29. Vichalkovski A, Gresko E, Cornils H, Hergovich A, Schmitz D, Hemmings BA. NDR kinase is activated by RASSF1A/MST1 in response to Fas receptor stimulation and promotes apoptosis. Curr Biol 2008; 18: 1889-1895.
30. Hambardzumyan D, Squatrito M, Holland EC. Radiation resistance and stem-like cells in brain tumors. Cancer Cell 2006; 10: 454-456.
31. McCord AM, Jamal M, Williams ES, Camphausen K, Tofilon PJ. CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines. Clin Cancer Res 2009; 15: 5145-5153.
32. Nakada M, Nakada S, Demuth T, Tran NL, Hoelzinger DB, Berens ME. Molecular targets of glioma invasion. Cell Mol Life Sci 2007; 64: 458-478.
33. Wu Y, Singh S, Georgescu MM, Birge RB. A role for Mer tyrosine kinase in alphavbeta5 integrin-mediated phagocytosis of apoptotic cells. J Cell Sci 2005; 118: 539-553.
34. Strick DJ, Feng W, Vollrath D. Mertk drives myosin II redistribution during retinal pigment epithelial phagocytosis. Invest Ophthalmol Vis Sci 2009; 50: 2427-2435.
35. Guttridge KL, Luft JC, Dawson TL, Kozlowska E, Mahajan NP, Varnum B et al. Mer receptor tyrosine kinase signaling: prevention of apoptosis and alteration of cytoskeletal architecture without stimulation or proliferation. J Biol Chem 2002; 277: 24057-24066.
36. Wolf K, Mazo I, Leung H, Engelke K, von Andrian UH, Deryugina EI et al. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol 2003; 160: 267-277.
37. Fackler OT, Grosse R. Cell motility through plasma membrane blebbing. J Cell Biol 2008; 181: 879-884.
38. Parri M, Chiarugi P. Rac and Rho GTPases in cancer cell motility control. Cell Commun Signal 2010; 8: 23.
39. Rogers AE, Le JP, Sather S, Pernu BM, Graham DK, Pierce AM et al. Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology. Oncogene 2011; doi:10.1038/onc.2011.588.
40. Cukierman E, Pankov R, Yamada KM. Cell interactions with three-dimensional matrices. Curr Opin Cell Biol 2002; 14: 633-639.
41. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-2392.
42. Wyckoff JB, Pinner SE, Gschmeissner S, Condeelis JS, Sahai E. ROCK-and myosindependent matrix deformation enables protease-independent tumor-cell invasion in vivo. Curr Biol 2006; 16: 1515-1523.
43. Rao J, Li N. Microfilament actin remodeling as a potential target for cancer drug development. Curr Cancer Drug Targets 2004; 4: 345-354.
44. Maier D, Comparone D, Taylor E, Zhang Z, Gratzl O, Van Meir EG et al. New deletion in low-grade oligodendroglioma at the glioblastoma suppressor locus on chromosome 10q25-26. Oncogene 1997; 15: 997-1000.
45. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109.
46. Hergovich A, Lamla S, Nigg EA, Hemmings BA. Centrosome-associated NDR kinase regulates centrosome duplication. Mol Cell 2007; 25: 625-634.
47. Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC et al. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999; 9: 469-479.
48. Clement V, Marino D, Cudalbu C, Hamou MF, Mlynarik V, de Tribolet N et al. Marker-independent identification of glioma-initiating cells. Nat Methods 2010; 7: 224-228.
49. Hergovich A, Lisztwan J, Barry R, Ballschmieter P, Krek W. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol 2003; 5: 64-70.